Literature DB >> 15057566

Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Zeki Yesilova1, Salih Pay, Cagatay Oktenli, Ugur Musabak, Kenan Saglam, S Yavuz Sanisoglu, Kemal Dagalp, M Kemal Erbil, Ismail H Kocar.   

Abstract

Considerable discrepancies exist in the literature with respect to plasma total homocysteine (tHcy) levels in Behçet's disease (BD). The aim of this study was to evaluate tHcy concentrations in these patients. Thirty-two patients with BD and 20 age- and body mass index-matched healthy volunteers were enrolled. Plasma tHcy concentrations were significantly higher, while vitamin B12 and folate levels were significantly lower in patients with thrombosis and eye involvement than those without. C-reactive protein levels also correlated significantly in a negative manner with vitamin B12 and folate but positively with tHcy. In conclusion, increased use or accelerated catabolism of folate and vitamin B12 due to chronic inflammation and moderately increased tHcy concentrations related with deficiency of these cofactors, and immunosuppressive drug administration might be potential threats of vascular disease in BD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057566     DOI: 10.1007/s00296-004-0466-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  59 in total

1.  Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.

Authors:  D Ducloux; V Fournier; J M Rebibou; C Bresson-Vautrin; R Gibey; J M Chalopin
Journal:  Clin Nephrol       Date:  1998-04       Impact factor: 0.975

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet's disease.

Authors:  K Köse; C Yazici; O Aşşioğlu
Journal:  Clin Biochem       Date:  2001-03       Impact factor: 3.281

4.  Behçet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity.

Authors:  A U Müftüoğlu; H Yazici; S Yurdakul; Y Tüzün; H Pazarli; G Güngen; S Deniz
Journal:  Int J Dermatol       Date:  1986-05       Impact factor: 2.736

5.  Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells.

Authors:  A Majors; L A Ehrhart; E H Pezacka
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

6.  Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients.

Authors:  D Ducloux; C Ruedin; R Gibey; P Vautrin; C Bresson-Vautrin; J M Rebibou; J M Chalopin
Journal:  Nephrol Dial Transplant       Date:  1998-11       Impact factor: 5.992

7.  B vitamin status and inflammatory markers.

Authors:  Aaron R Folsom; Moïse Desvarieux; F Javier Nieto; Lori L Boland; Christie M Ballantyne; Lloyd E Chambless
Journal:  Atherosclerosis       Date:  2003-07       Impact factor: 5.162

8.  Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment.

Authors:  A Yxfeldt; S Wållberg-Jonsson; J Hultdin; S Rantapää-Dahlqvist
Journal:  Scand J Rheumatol       Date:  2003       Impact factor: 3.641

9.  Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid-additional mechanisms in homocysteine induced endothelial damage?

Authors:  G Frauscher; E Karnaukhova; A Muehl; H Hoeger; B Lubec
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

10.  Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients.

Authors:  M Arnadottir; B Hultberg; V Vladov; P Nilsson-Ehle; H Thysell
Journal:  Transplantation       Date:  1996-02-15       Impact factor: 4.939

View more
  7 in total

1.  5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behcet's patients with or without ocular involvement.

Authors:  Y Ozkul; C Evereklioglu; M Borlu; S Taheri; M Calis; M Dündar; O Ilhan
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

2.  Thymidylate synthase genotype and serum concentrations of homocysteine and folate in Behçet's disease.

Authors:  N Düzgün; T Duman; Y Morris; H Tutkak; K Köse; E Ertuğrul; O Tiryaki Aydintuğ
Journal:  Clin Rheumatol       Date:  2008-05-06       Impact factor: 2.980

3.  Homocysteine levels in patients with Behçet's disease and patients with recurrent aphthous stomatitis.

Authors:  Müzeyyen Gönül; Ulker Gül; Cumhur Kilinç; Seray Külcü Cakmak; Seçil Soylu; Arzu Kiliç
Journal:  Clin Rheumatol       Date:  2009-07-03       Impact factor: 2.980

4.  Hyperhomocysteinaemia in Behçet's Disease.

Authors:  Amira Hamzaoui; Olfa Harzallah; Rim Klii; Silvia Mahjoub
Journal:  Biochem Res Int       Date:  2010-09-28

5.  Complement C3: an emerging risk factor in cardiometabolic disease.

Authors:  E Hertle; M M J van Greevenbroek; C D A Stehouwer
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

6.  Evaluation of Serum Homocysteine and Leptin Levels in Patients with Uveitis.

Authors:  Arif Emre Elbay; Ayşen Topalkara; Ahmet Elbay; Haydar Erdoğan; Ayşe Vural; Abdi Bahadır Çetin
Journal:  Turk J Ophthalmol       Date:  2015-08-05

7.  Homocysteine may involve in the pathogenesis of Behcet's disease by inducing inflammation.

Authors:  Selda Pelin Kartal Durmazlar; Ahmet Akgul; Fatma Eskioglu
Journal:  Mediators Inflamm       Date:  2009-02-01       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.